Benchmark restated their speculative buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a research note released on Friday morning,Benzinga reports. The firm currently has a $3.00 price objective on the stock.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $5.13.
View Our Latest Research Report on UNCY
Unicycive Therapeutics Stock Performance
Shares of UNCY stock remained flat at $0.53 during mid-day trading on Friday. 872,401 shares of the stock traded hands, compared to its average volume of 1,923,005. The firm has a market cap of $55.01 million, a price-to-earnings ratio of -0.55 and a beta of 2.29. The company has a fifty day simple moving average of $0.44 and a 200-day simple moving average of $0.53. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82.
Hedge Funds Weigh In On Unicycive Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its holdings in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after acquiring an additional 62,881 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter worth approximately $29,000. Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth approximately $2,040,000. Acuta Capital Partners LLC purchased a new stake in Unicycive Therapeutics in the 3rd quarter valued at approximately $807,000. Finally, Great Point Partners LLC purchased a new stake in Unicycive Therapeutics in the 3rd quarter valued at approximately $3,491,000. 40.42% of the stock is owned by institutional investors and hedge funds.
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Stories
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
